CGRP Inhibitors for Migraines: Slight Rise in Stroke Risk

Research Summary

A study published in Neurology explores the cardiovascular risks associated with Calcitonin Gene-Related Peptide (CGRP) inhibitors used for migraine treatment. Researchers analyzed insurance data from 900,370 individuals, finding that those who initiated CGRP inhibitors had a slightly higher risk of cardiovascular events, including strokes, compared to those who did not (9 events/1,000 person-years vs 7 events/1,000 person-years; adjusted hazard ratio 1.26). The study highlights a modest increase in risk for ischemic strokes, though not for heart attacks or other vascular issues. These findings offer important insights into the safety profile of CGRP inhibitors for migraine patients.

Study Details

📄 Title: Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine: A Retrospective, Observational Cohort Study.

👥 Research Team: Lusk JB et al.

📚 Published In: Neurology

📅 Publication Date: 2026 Feb 10

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.